Iwata, Y
Nakajima, S
Suzuki, T
Keefe, R S E
Plitman, E
Chung, J K
Caravaggio, F
Mimura, M
Graff-Guerrero, A
Uchida, H
Article History
Received: 23 February 2015
Revised: 16 April 2015
Accepted: 27 April 2015
First Online: 16 June 2015
Competing interests
: YI has received manuscript fees from Wiley Japan within the past 3 years. SN has received fellowship grants from the CIHR and Japan Society for the Promotion of Science, and manuscript fees from Dainippon Sumitomo Pharma and Kyowa Hakko Kirin. TS has received manuscript or speaker’s fees from Astellas, Dainippon Sumitomo, Eli Lilly, Elsevier Japan, Janssen, Meiji Seika, Novartis, Otsuka and Wiley Japan within the past 3 years. RSEK currently or in the past 3 years has received investigator-initiated research funding support from the Department of Veteran’s Affair, Feinstein Institute for Medical Research, GlaxoSmithKline, National Institute of Mental Health, Novartis, Psychogenics, Research Foundation for Mental Hygiene and the Singapore National Medical Research Council. He currently or in the past 3 years has received honoraria, served as a consultant, or advisory board member for Abbvie, Akebia, Amgen, Astellas, Asubio, AviNeuro/ChemRar, BiolineRx, Biogen Idec, Biomarin, Boehringer-Ingelheim, Eli Lilly, FORUM, GW Pharmaceuticals, Helicon, Lundbeck, Merck, Minerva Neurosciences, Mitsubishi, Novartis, Otsuka, Pfizer, Roche, Shire, Sunovion, Takeda, Targacept and WWCT. RSEK receives royalties from the BACS testing battery, the MATRICS Battery (BACS Symbol Coding) and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). He is also a shareholder in NeuroCog Trials and Sengenix. EP has received the Ontario Graduate Scholarship and the Canada Graduate Scholarship. FC has received the Ontario Graduate Scholarship and the Canada Graduate Scholarship. MM has received grants and/or speaker’s honoraria from Asahi Kasei Pharma, Astellas Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Meiji-Seika Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi Pharma and Yoshitomi Yakuhin within the past 3 years. AG has received research support from the following external funding agencies: the Canadian Institutes of Health Research (CIHR), US National Institute of Health, Ontario Mental Health Foundation, Brain and Behavior Research Foundation, Mexico ICyTDF, CONACyT, Ministry of Economic Development and Innovation of Ontario, Ontario AHSC AFP Innovation Fund and W Garfield Weston Foundation. HU has received grants from Astellas Pharmaceutical, Eisai, Otsuka Pharmaceutical, GlaxoSmithKline, Shionogi, Dainippon-Sumitomo Pharma, Eli Lilly, Mochida Pharmaceutical, Meiji-Seika Pharma and Yoshitomi Yakuhin and speaker’s honoraria from Otsuka Pharmaceutical, Eli Lilly, Shionogi, GlaxoSmithKline, Yoshitomi Yakuhin, Dainippon-Sumitomo Pharma, Meiji-Seika Pharma, Abbvie, MSD and Janssen Pharmaceutical within the past 2 years. Other authors have no financial or other relationship relevant to the subject of this manuscript.